StoneRidge PMG Advisors LLC Makes New Investment in Elevance Health, Inc. $ELV

StoneRidge PMG Advisors LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,335 shares of the company’s stock, valued at approximately $908,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. University of Texas Texas AM Investment Management Co. lifted its position in Elevance Health by 12.0% during the third quarter. University of Texas Texas AM Investment Management Co. now owns 374 shares of the company’s stock valued at $145,000 after acquiring an additional 40 shares during the last quarter. M Holdings Securities Inc. purchased a new stake in Elevance Health in the third quarter valued at about $305,000. Brighton Jones LLC grew its stake in shares of Elevance Health by 48.4% during the third quarter. Brighton Jones LLC now owns 6,025 shares of the company’s stock worth $2,343,000 after acquiring an additional 1,965 shares during the last quarter. Candriam S.C.A. grew its stake in shares of Elevance Health by 49.9% during the third quarter. Candriam S.C.A. now owns 91,310 shares of the company’s stock worth $35,633,000 after acquiring an additional 30,409 shares during the last quarter. Finally, 180 Wealth Advisors LLC acquired a new position in shares of Elevance Health during the third quarter valued at about $600,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Ratnakar Lavu sold 1,300 shares of the company’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $440.00, for a total value of $572,000.00. Following the completion of the transaction, the executive vice president owned 14,849 shares of the company’s stock, valued at approximately $6,533,560. This represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mark Kaye sold 10,584 shares of the stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the transaction, the chief financial officer owned 19,919 shares in the company, valued at $8,766,949.47. This represents a 34.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.34% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on ELV. Guggenheim increased their price objective on shares of Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Wells Fargo & Company boosted their target price on shares of Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 27th. Weiss Ratings restated a “hold (c)” rating on shares of Elevance Health in a research note on Thursday, August 13th. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday. Finally, TD Cowen raised their price target on shares of Elevance Health from $465.00 to $495.00 and gave the stock a “buy” rating in a report on Friday, October 23rd. Fifteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $456.48.

Elevance Health Trading Up 0.1%

Elevance Health stock opened at $426.17 on Monday. The firm has a market cap of $92.08 billion, a PE ratio of 18.17, a P/E/G ratio of 2.03 and a beta of 0.63. Elevance Health, Inc. has a 12 month low of $274.84 and a 12 month high of $450.69. The stock’s 50 day simple moving average is $412.92 and its two-hundred day simple moving average is $373.58. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The firm had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. During the same period in the previous year, the firm earned $6.03 EPS. The business’s quarterly revenue was up .7% on a year-over-year basis. Analysts anticipate that Elevance Health, Inc. will post 29.15 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s payout ratio is currently 29.34%.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Elevance Health Profile

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.